|
Jun 14
|
OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders
|
|
Jun 11
|
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
|
|
Jun 11
|
OKYO Pharma to Present at the Bio International Convention
|
|
May 1
|
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
|
|
Apr 30
|
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
|
|
Jul 11
|
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
|
|
Jul 10
|
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
|
|
Jan 31
|
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
|
|
Jan 5
|
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
|
|
Dec 4
|
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
|
|
Apr 25
|
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
|